Phase 2 efficacy and pharmacodynamic study of 2-methoxyestradiol nanocrystal colloidal dispersion (Panzem NCD) in patients with taxane-refractory, metastatic, hormone-refractory prostate cancer

Trial Profile

Phase 2 efficacy and pharmacodynamic study of 2-methoxyestradiol nanocrystal colloidal dispersion (Panzem NCD) in patients with taxane-refractory, metastatic, hormone-refractory prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs 2-methoxyestradiol (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals; EntreMed
  • Most Recent Events

    • 24 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
    • 09 Jul 2008 The expected completion date for this trial has been changed form June 2008 to Sep 2008, as reported by ClinicalTrials.gov.
    • 06 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top